22633-57-4

Basic information

• Product Name: Morpholin-4-yl-acetaldehyde, diMethyl acetal
• Synonyms: Morpholin-4-yl-acetaldehyde, diMethyl acetal
• CAS NO: 22633-57-4
• Molecular Formula: C₈H₁₇NO₃
• Molecular Weight: 189.209
• Mol File: 22633-57-4.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 81.5-83 °C(Press: 5 Torr)
• Appearance: /
• Density: 1.017±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 7.16±0.10(Predicted)
• CAS DataBase Reference: Morpholin-4-yl-acetaldehyde, diMethyl acetal(CAS DataBase Reference)
• NIST Chemistry Reference: Morpholin-4-yl-acetaldehyde, diMethyl acetal(22633-57-4)
• EPA Substance Registry System: Morpholin-4-yl-acetaldehyde, diMethyl acetal(22633-57-4)

Safety Data

• Hazardous Substances Data: 22633-57-4(Hazardous Substances Data)

Usage

General Description

Morpholin-4-yl-acetaldehyde, diMethyl acetal is a chemical compound with the molecular formula C8H17NO3. It is a colorless liquid with a fruity odor, often used as a fragrance ingredient and flavoring agent in the food and beverage industry. This chemical is also used as a solvent in various industrial processes and as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It is important to handle this chemical with caution, as it can be harmful if ingested, inhaled, or in contact with skin. Proper safety measures and protective equipment should be used when working with this chemical to prevent any potential hazards.

Upstream product

• 110-91-8 morpholine 
• 97-97-2 chloroacetaldehyde dimethyl acetal 
• 51673-84-8 dimethoxyacetaldehyde 
• 7252-83-7 1-bromo-2,2-dimethoxyethane 

Downstream Products

• 1172495-88-3 morpholin-4-yl-acetaldehyde hydrochloride 
• 1420404-08-5 (Z)-(S)-N-(4-((3-chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-2-fluoro-4-morpholinobut-2-enamide 
• 1420404-12-1 (E)-(S)-N-(4-((3-chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-2-fluoro-4-morpholinobut-2-enamide 
• 1420404-24-5 (Z)-N-(4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-4-morpholinobut-2-enamide 
• 1420404-28-9 (E)-N-(4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-4-morpholinobut-2-enamide 
• 21977-09-3 morpholin-4-ylacetaldehyde 

Relevant articles and documents

COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF KRAS

Bifunctional compounds, which find utility as modulators of Kirsten ras sarcoma protein (KRas or KRAS), are described herein. In particular, the hetero-bifunctional compounds of the present disclosure contain on one end a moiety that binds to the Von Hippel-Lindau E3 ubiquitin ligase and on the other end a moiety which binds KRas, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The heterobifunctional compounds of the present disclosure exhibit a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aberrant regulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

A chemical tuned strategy to develop novel irreversible EGFR-TK inhibitors with improved safety and pharmacokinetic profiles

Gatekeeper T790 M mutation in EGFR is the most prevalent factor underlying acquired resistance. Acrylamide-bearing quinazoline derivatives are powerful irreversible inhibitors for overcoming resistance. Nevertheless, concerns about the risk of nonspecific covalent modification have motivated the development of novel cysteine-targeting inhibitors. In this paper, we demonstrate that fluoro-substituted olefins can be tuned to alter Michael addition reactivity. Incorporation of these olefins into the quinazoline templates produced potent EGFR inhibitors with improved safety and pharmacokinetic properties. A lead compound 5a was validated against EGFRWT, EGFRT790M as well as A431 and H1975 cancer cell lines. Additionally, compound 5a displayed a weaker inhibition against the EGFR-independent cancer cell line SW620 when compared with afatinib. Oral administration of 5a at a dose of 30 mg/kg induced tumor regression in a murine-EGFRL858R/T790M driven H1975 xenograft model. Also, 5a exhibited improved oral bioavailability and safety as well as favorable tissue distribution properties and enhanced brain uptake. These findings provide the basis of a promising strategy toward the treatment of NSCLC patients with drug resistance.